<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452543</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-001592/1</org_study_id>
    <nct_id>NCT00452543</nct_id>
  </id_info>
  <brief_title>Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study about treatment for people who suffer from both major depression and alcohol
      abuse or dependence. The study will examine whether the addition of acamprosate to
      escitalopram and behavioral interventions will improve outcomes for this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression and alcohol use disorders contribute to a significant proportion of the burden of
      disease, in the United States and abroad. Patients who suffer from co-morbid depression and
      alcohol abuse/dependence have illnesses that are more severe, persistent and costly than
      people with either depression or an alcohol use disorder alone. The treatment of these
      patients remains controversial. Several studies have demonstrated that antidepressants can be
      safe and efficacious in the treatment of depression in people who continue to drink, and it
      is now considered the standard of care to provide such treatment. Other studies have shown
      that pharmacotherapy with naltrexone or acamprosate can help reduce drinking in alcoholics
      without co-morbid depression. A logical extension of these findings would be to study the
      treatment of depressed alcoholics with dual pharmacotherapy, combining an anti-depressant
      with a medication aimed at treating the alcohol use disorder. We will conduct a randomized,
      double-blind, placebo controlled trial of escitalopram plus acamprosate and behavioral
      treatment vs. escitalopram plus placebo and behavioral treatment in 20 depressed alcoholics.
      Outcome measures will include depression, alcohol use and global functioning.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)</measure>
    <time_frame>From baseline visit to Week 12 (or early discontinuation visit)</time_frame>
    <description>Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Drinking Days on the Alcohol Timeline Followback (TLFB)</measure>
    <time_frame>From Baseline visit to Week 12 (or early discontinuation visit)</time_frame>
    <description>The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Drinks Consumed Per Week on the TLFB</measure>
    <time_frame>From Baseline visit to Week 12 (or early discontinuation visit)</time_frame>
    <description>Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Drinks Consumed Per Drinking Day on the TLFB</measure>
    <time_frame>From Baseline visit to Week 12 (or early discontinuation visit)</time_frame>
    <description>Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Escitalopram plus acamprosate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acamprosate</intervention_name>
    <description>Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.</description>
    <arm_group_label>Escitalopram plus acamprosate</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.</description>
    <arm_group_label>Escitalopram plus acamprosate</arm_group_label>
    <arm_group_label>Escitalopram plus placebo</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical management</intervention_name>
    <description>Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).</description>
    <arm_group_label>Escitalopram plus acamprosate</arm_group_label>
    <arm_group_label>Escitalopram plus placebo</arm_group_label>
    <other_name>Campral and Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 capsules PO TID, for 12 weeks</description>
    <arm_group_label>Escitalopram plus placebo</arm_group_label>
    <other_name>Campral and Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DSM-IV diagnostic criteria for MDD (diagnosis based on Structured Clinical Interview
             for DSM-IV, Patient Edition; SCID I/P)

          2. Written informed consent

          3. Men and women aged 18-64 years

          4. Current diagnosis of alcohol abuse/dependence as per SCID I/P

        Exclusion Criteria:

          1. Subjects with suicidal ideation where outpatient treatment is determined unsafe by the
             study clinician. These patients will be immediately referred to appropriate clinical
             treatment.

          2. Pregnant women or women of childbearing potential who are not using a medically
             accepted means of contraception (defined as oral contraceptive pill or implant,
             condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy).

          3. Known history of serious or unstable medical illness, including cardiovascular,
             hepatic, renal, respiratory, endocrine, neurologic or hematologic disease.

          4. History of seizure disorder, brain injury, any history of known neurological disease
             (multiple sclerosis, degenerative disease such as ALS, Parkinson disease and any
             movement disorders, etc.).

          5. Clinical or lab evidence of untreated hypothyroidism.

          6. History or current diagnosis of the following DSM-IV psychiatric illness: organic
             mental disorder, schizophrenia, schizoaffective disorder, delusional disorder,
             psychotic disorders not otherwise specified, bipolar disorder, patients with mood
             congruent or mood incongruent psychotic features, patients with substance use
             disorders (excluding alcohol and nicotine) active within the last 12 months.

          7. Current use of other psychotropic drugs, including current use of benzodiazepines,
             hypnotics, anticonvulsants. Concomitant use of antihistamine drugs will be allowed.
             Patients will need to be off all antidepressants for at least two weeks by the time of
             the baseline visit, and four weeks for fluoxetine, and off benzodiazepines and other
             psychotropics for at least one week. The decision about whether to taper existing
             medications should be made by the individual and their primary treater based on
             clinical care and will not be made for purposes of study enrollment. allowed.

          8. Patients who have failed to respond during the course of their current major
             depressive episode to at least two adequate antidepressant trials. An adequate
             antidepressant trial is defined as six weeks or more of treatment with escitalopram &gt;
             20mg/day or its antidepressant equivalent: (fluoxetine 40mg/day, sertraline &gt; 100
             mg/day, paroxetine &gt; 40 mg/day, fluvoxamine &gt; 100 mg/day, citalopram &gt; 40 mg/day,
             escitalopram &gt; 20 mg/day, venlafaxine &gt; 150 mg/day, and duloxetine &gt; 60 mg/day).

          9. Any depression-focused or substance-abuse focused psychotherapy (family or marital
             counseling would be allowed).

         10. Patients who have taken an investigational psychotropic drug within the past year.

         11. Need for medical or inpatient detoxification from alcohol. This determination will be
             made by the screening clinician, based on clinical judgement as in the multicenter
             STAR*D study (PHRC #2000-P-001955 in accordance with methods used in the multi-center
             STAR-D study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet M Witte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Bolo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <results_first_submitted>May 24, 2011</results_first_submitted>
  <results_first_submitted_qc>June 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2012</results_first_posted>
  <last_update_submitted>June 4, 2012</last_update_submitted>
  <last_update_submitted_qc>June 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet Melissa Witte</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol abuse</keyword>
  <keyword>Alcohol dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram Plus Acamprosate</title>
          <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
        </group>
        <group group_id="P2">
          <title>Escitalopram Plus Placebo</title>
          <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram Plus Acamprosate</title>
          <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
        </group>
        <group group_id="B2">
          <title>Escitalopram Plus Placebo</title>
          <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="13"/>
                    <measurement group_id="B2" value="43" spread="14"/>
                    <measurement group_id="B3" value="47" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)</title>
        <description>Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit.</description>
        <time_frame>From baseline visit to Week 12 (or early discontinuation visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram Plus Acamprosate</title>
            <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram Plus Placebo</title>
            <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)</title>
          <description>Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="8.5"/>
                    <measurement group_id="O2" value="-7.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Drinking Days on the Alcohol Timeline Followback (TLFB)</title>
        <description>The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit.</description>
        <time_frame>From Baseline visit to Week 12 (or early discontinuation visit)</time_frame>
        <population>Intent to treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram Plus Acamprosate</title>
            <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram Plus Placebo</title>
            <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
          </group>
        </group_list>
        <measure>
          <title>Total Drinking Days on the Alcohol Timeline Followback (TLFB)</title>
          <description>The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit.</description>
          <population>Intent to treat sample</population>
          <units>Drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="53" lower_limit="8" upper_limit="114"/>
                    <measurement group_id="O2" value="61" spread="86" lower_limit="-25" upper_limit="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analyses evaluated the null hypothesis that there would be no difference in the effect of acamprosate vs. placebo on total drinking days.Power analysis was originally based on ITT analysis with 40 subjects, and assumed 30% difference in alcohol consumption (50% vs. 20% reduction in the acamprosate and placebo groups, respectively). With alpha of 0.05, we estimated 74% power to detect a difference between the two groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was a test of non-inferiority between the effects of acamprosate vs. placebo. Power analysis was originally based on ITT analysis with 40 subjects, and assumed 30% difference in alcohol consumption (50% vs. 20% reduction in the acamprosate and placebo groups, respectively). With alpha of 0.05, we estimated 74% power to detect a difference between the two groups. Results would be used to estimate effect size to set the stage for an adequately powered larger study in the future.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Threshold for significance was set a priori at p&lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Drinks Consumed Per Week on the TLFB</title>
        <description>Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit.</description>
        <time_frame>From Baseline visit to Week 12 (or early discontinuation visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram Plus Acamprosate</title>
            <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram Plus Placebo</title>
            <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
          </group>
        </group_list>
        <measure>
          <title>Total Drinks Consumed Per Week on the TLFB</title>
          <description>Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit.</description>
          <units>Drinks consumed per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="13" lower_limit="2" upper_limit="28"/>
                    <measurement group_id="O2" value="15" spread="21" lower_limit="-6" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analyses evaluated the null hypothesis that there would be no difference in the effect of acamprosate vs. placebo on total drinks consumed per week.Power analysis was originally based on ITT analysis with 40 subjects, and assumed 30% difference in alcohol consumption (50% vs. 20% reduction in the acamprosate and placebo groups, respectively). With alpha of 0.05, we estimated 74% power to detect a difference between the two groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was a test of non-inferiority between the effects of acamprosate vs. placebo.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>This p &lt;0.05 was set a priori.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Drinks Consumed Per Drinking Day on the TLFB</title>
        <description>Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit.</description>
        <time_frame>From Baseline visit to Week 12 (or early discontinuation visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram Plus Acamprosate</title>
            <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram Plus Placebo</title>
            <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
          </group>
        </group_list>
        <measure>
          <title>Total Drinks Consumed Per Drinking Day on the TLFB</title>
          <description>Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit.</description>
          <units>Drinks consumed per drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="4" spread="4" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analyses evaluated the null hypothesis that there would be no difference in the effect of acamprosate vs. placebo on total drinks consumed per drinking day.
Power analysis was originally based on ITT analysis with 40 subjects, and assumed 30% difference in alcohol consumption (50% vs. 20% reduction in the acamprosate and placebo groups, respectively). With alpha of 0.05, we estimated 74% power to detect a difference between the two groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was a test of non-inferiority between the effects of acamprosate vs. placebo. Statistical analyses evaluated the null hypothesis that there would be no difference in the effect of acamprosate vs. placebo on total drinks consumed per drinking day.
Power analysis is discussed above.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>This p&lt;0.05 was set a priori.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram Plus Acamprosate</title>
          <description>Escitalopram 10-30mg/day plus acamprosate 333mg, 2 tabs tid</description>
        </group>
        <group group_id="E2">
          <title>Escitalopram Plus Placebo</title>
          <description>Escitalopram 10-30mg/day plus placebo 2 tabs tid that resembles acamprosate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Blockage in the coronary artery</sub_title>
                <description>Subject had sudden onset of shortness of breath and chest pain. A blockage was discovered in the coronary artery, requiring that a stent be implanted. The patient was hospitalized for 4 days.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for alcohol intoxication</sub_title>
                <description>Subject was admitted to a detox unit after found intoxicated and passed out. Subject was discharged 3 days following from the inpatient unit to an outpatient program.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increased gag reflex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Soft stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Jaw tightening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry lips</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Janet Witte</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-5104</phone>
      <email>jwitte@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

